Mr. David Regan reports

SONA NANOTECH ANNOUNCES FILING OF PROVISIONAL PATENT APPLICATION

Sona Nanotech Inc. has submitted a provisional patent application with the United States Patent and Trademark Office (USPTO), for its proprietary photothermal light device, entitled, "Endoscope with EMR Optical Fiber and Thermal Sensor for Photothermal Therapy."

A prototype of Sona's medical laser was engineered in conjunction with Minnetronix Medical to apply non-thermal, 860-nanometre wavelength high-intensity infrared laser light. The device has been designed for use with Sona's patented/patent-pending biocompatible gold nanorods which efficiently convert the non-thermal light energy into heat. The device has controls to regulate the intensity and duration of the light exposure and to permit a user to monitor and control the temperature generated in tissue. The device is currently being used for the company's continuing preclinical efficacy study of its Targeted Hyperthermia therapy cancer treatment at Dalhousie University.

The company also recently met with a group of leading surgeons and payer representatives in the U.S. as part of its second EXCITE International panel discussion. That roundtable evaluation and discussion, together with its recent presubmission meeting with the U.S. Food and Drug Administration (FDA), provided important feedback and guidance to the company on the development and validation path for its Targeted Hyperthermia therapy cancer therapy. Sona Nanotech chief executive officer David Regan commented: "Sona's recent roundtable session with its panel of surgeons from leading U.S. academic medical centres and medical payment organizations provided us with invaluable counsel on considerations for both the indications for use for Sona's Targeted Hyperthermia therapy and the research data that may be required to secure payment codes from payers. This guidance, together with recent feedback received from the FDA, gives us confidence in the appropriateness of our research study pathway and the likelihood of acceptance by physicians and health care institutions of our cancer treatment. The company continues to develop the data on the safety and efficacy of its therapy to support an eventual regulatory submission with its current study at Dalhousie University Medical School."

Finally, the company recently named Dr. Carman Giacomantonio, MD, MSc, FRCSC, to its advisory board. Dr. Giacomantonio is a surgical oncologist and professor of surgery whose research focuses on the mechanism of action of interleukin-2 therapy in the treatment of melanoma and breast and colorectal cancer. Dr. Giacomantonio is the principal investigator for the company's current preclinical efficacy study at Dalhousie University.

About Sona Nanotech Inc.

Sona Nanotech, a nanotechnology life sciences company, is developing Targeted Hyperthermia, a photothermal cancer therapy, which uses therapeutic heat to treat solid cancer tumours. The heat is delivered to tumours by infrared light that is absorbed by Sona's gold nanorods in the tumour and re-emitted as heat. Therapeutic heat (41 to 48 degrees) stimulates the immune system, shrinks tumours, inactivates cancer stem cells and increases tumour perfusion -- thus enabling drugs to reach all tumour compartments more effectively. The size, shape and surface chemistry of the nanorods target the leaky vasculature of solid tumours, and the selective thermal sensitivity of tumour tissue enables the therapy to deliver clean margins. Targeted Hyperthermia promises to be safe, effective, minimally invasive, competitive in cost, and a valuable adjunct to drug therapy and other cancer treatments.

Sona has developed multiple proprietary methods for the manufacture of gold nanoparticles which it uses for the development of both cancer therapies and diagnostic testing platforms. Sona Nanotech's gold nanorod particles are cetyltrimethylammonium-free (CTAB), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. It is expected that Sona's gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, subject to the approval of various regulatory boards, including Health Canada and the FDA.

We seek Safe Harbor.